Compare Cassava Sciences Inc (FLNA) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Ryanair Holdings plc — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Ryanair Holdings plc trades at $66.44 (market cap $31.83B). The key difference: Ryanair Holdings plc is far larger — about 599× Cassava Sciences Inc's market cap, and Ryanair Holdings plc pays a 1.48% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | RYAAY | |
|---|---|---|
Market Cap | $53.14M | $31.83B |
Sector | Health | Industrials |
52-Week High | $4.64 | $73.82 |
52-Week Low | $1.09 | $53.24 |
Enterprise Value | -$33.43M | $29.49B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
RYAAY trades at $66.29, up 3.11% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 14.32, net income margin of 13.98%, and consistent earnings beats. Recent news highlights passenger growth and operational updates, though a window incident adds scrutiny. Cash flow remains positive from operations at $3.42B despite negative net cash flow.
Outlook is positive with analyst consensus at 62.5% buy ratings. Revenue growth to $15.5B projected for 2026 supports upside, but risks include fuel cost volatility and regulatory pressures. The stock's valuation and profitability metrics present an attractive entry for long-term investors amid sector recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
